Veeva Systems Inc. hits a 20-day low amid market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Should l Buy VEEV?
Source: Benzinga
Veeva Systems Inc. experienced a price decline of 4.21%, hitting a 20-day low. This movement comes as the Nasdaq-100 is down 0.52% and the S&P 500 is down 0.18%, indicating a broader market weakness.
The decline in Veeva's stock price is attributed to sector rotation, as investors are shifting their focus away from certain tech stocks that are underperforming despite the overall market's bullish trend. This trend suggests that some stocks, including Veeva, may be facing deeper issues that require closer examination.
Investors should remain cautious as the market dynamics shift, particularly in the tech sector, where not all companies are benefiting equally from the current market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VEEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VEEV
Wall Street analysts forecast VEEV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VEEV is 317.10 USD with a low forecast of 222.00 USD and a high forecast of 380.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
23 Analyst Rating
16 Buy
6 Hold
1 Sell
Moderate Buy
Current: 183.850
Low
222.00
Averages
317.10
High
380.00
Current: 183.850
Low
222.00
Averages
317.10
High
380.00
About VEEV
Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. It offers span cloud software, data, and business consulting and is designed to meet the needs of its customers and the strategic business functions from research and development (R&D) through commercialization. Its four product categories include Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Quality Cloud unifies applications, processes, and partners across content management, training, quality management, assurance, and control lab solutions on the Veeva Vault platform. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. Veeva Data Cloud is a data platform comprised of connected reference data, deep data, and transaction data.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Standardization of Customer Engagement: Veeva Link Key People has been adopted as a standard by 13 of the top 20 biopharma companies, enhancing customer engagement and providing data support globally, which is expected to significantly improve customer relationships and market responsiveness.
- New Client Growth: In the past year, Veeva Link Key People added 38 new clients, including three of the world's leading biopharma companies, indicating widespread recognition and demand in the industry, further solidifying Veeva's market position.
- Data-Driven Decision Making: Bayer AG's VP stated that the integration of Link Key People data has become central to their decision-making process, enhancing precision marketing capabilities and facilitating interactions with healthcare professionals, ultimately aiding in patient care improvement.
- Technological Innovations: Veeva enhances customer interaction experiences through innovations such as AI-driven summaries, personalized notifications, and new data sources, while the Link Direct API provides rapid data access, further driving digital transformation in the biopharma industry.
See More
- Standardization of Client Interactions: Veeva Systems announced that 13 out of the top 20 biopharmaceutical companies have standardized on Veeva Link Key People, a move that enhances client interactions through structured data, which is expected to significantly improve customer relationship management and market responsiveness.
- New Client Growth: Over the past year, Veeva Link Key People has added 38 new clients, including 3 of the top global biopharmaceutical companies, which not only strengthens Veeva's market position but also lays a foundation for future growth.
- Data-Driven Decision Making: The integration of Veeva Link Key People has made data central to decision-making for companies like Bayer, enhancing the accuracy and efficiency of data analysis, thereby driving innovation in AI-based healthcare solutions that ultimately improve patient care.
- Enhanced API Access: The newly launched API Link Direct Data provides data teams with quick access to Veeva data, an innovation that will further promote data integration and utilization within the biopharmaceutical industry, driving strategic collaboration and development across the sector.
See More
- Standardization Boost: In the past year, 13 of the top 20 biopharma companies have adopted Veeva Link Key People as their global standard, with 38 new customers added, showcasing its widespread recognition and application in the industry.
- Data-Driven Decision Making: Veeva Link Key People enhances decision-making for medical and commercial teams by providing trusted insights, while also feeding AI models with rich data sources, facilitating more efficient customer interactions.
- Innovative Features Introduced: New features such as AI-powered summaries, personalized notifications, and new digital data sources further improve the quality of customer interactions and help uncover new engagement opportunities, driving business growth.
- Deepening Strategic Partnerships: As part of Veeva Data Cloud, Veeva Link Key People utilizes Common Data Architecture (CDA) to connect data and software, strengthening strategic relationships with customers and promoting deep collaboration and development within the industry.
See More
- Standardization by Clients: In the past year, 13 of the top 20 biopharma companies have standardized on Veeva Link Key People to enhance customer engagement and provide data for AI globally, reflecting the industry's strong emphasis on data-driven decision-making.
- Customer Growth: Veeva Link Key People added 38 new customers in the last year, including three top biopharma companies adopting it as their global standard, further solidifying Veeva's market position in the biopharma sector.
- Data-Driven Decision Making: Link Key People enhances decision-making for medical and commercial teams by providing trusted insights, while also supplying data for analytics teams to support AI models, ultimately benefiting patient healthcare in the long term.
- Innovative Features: New functionalities of Veeva Link Key People, such as AI-powered summaries and personalized notifications, further improve customer interactions and help uncover new engagement opportunities, enhancing the overall customer experience.
See More
- Customer Engagement Boost: Veeva Systems announced that 13 of the 20 largest biopharma companies have standardized on Veeva Link Key People, significantly enhancing customer engagement and driving data-driven decision-making, thereby improving patient care quality.
- Significant Customer Growth: Over the past year, Veeva Link Key People added 38 new customers, including 3 of the top 20 global biopharma companies, indicating widespread recognition and application of the platform within the industry, further solidifying Veeva's market leadership.
- Innovation-Driven Interaction: Veeva Link Key People enhances customer interaction through innovations like AI-driven summaries, personalized notifications, and new digital data sources, helping biopharma companies discover new customer relationship opportunities and thereby increasing market competitiveness.
- Data Architecture Integration: As part of Veeva Data Cloud, Link Key People utilizes Veeva's Common Data Architecture to achieve seamless integration of data and software, enhancing data access speed and supporting analytics teams in building more accurate AI models, driving business growth.
See More
- Standardization by Clients: In the past year, 13 of the top 20 biopharma companies have standardized on Veeva Link Key People, with 38 new customers added, demonstrating its widespread recognition and application in the industry.
- Data-Driven Decision Making: Veeva Link Key People enhances data-driven decision-making by providing trusted customer insights, enabling pharmaceutical companies to achieve more precise market targeting, thereby improving patient care quality.
- AI Innovation Applications: Recent innovations in Veeva Link Key People include AI-powered summaries and personalized notifications, which not only improve customer interactions but also help uncover new engagement opportunities, driving business growth.
- Efficient API Access: The Link Direct Data API provides data teams with high-speed access to data, further enhancing the value of Veeva's products and ensuring that biopharma companies can quickly obtain the information needed to support their AI model development.
See More










